Triple Helix Discovery Engine
Triple Helix Framework
Industry
Architects: Small & Medium Size Business (SMBs), Product Development, De-Risking, Validation, Building Niche & Emerging Markets
*Architects: BioPharmaceutical Drug Discovery & Development_Artificial Intelligence (AI) & Machine Learning (ML)
Phare Bio

Organization & Developments: Phare Bio

Parents

*Generative AI platform for novel antibiotic discovery
*Phare advances antibiotics against high-priority pathogens through the “valley of death” -- the stage in early development when most drugs fail -- with donor and grant funding
*Phare Bio is a recipient of the Audacious Project, a collaborative funding initiative between TED and other nonprofits to unlock social impact on a grand scale
*Phare Bio is a social venture using artificial intelligence (AI) to develop novel classes of antibiotics in partnership with Jim Collins' lab at MIT and Harvard’s Wyss Institute
2024: ARPA-H_TARGET (Transforming Antibiotic R&D with Generative AI to stop Emerging Threats)
2024: Phare Bio Awarded Up To $27 Million from ARPA-H to Accelerate AI-Powered Drug Discovery and Develop Critically Needed New Classes of Antibiotics
2024: TARGET will be led by Phare Bio, along with the Collins Lab at the Massachusetts Institute of Technology (MIT) and Harvard’s Wyss Institute, with a budget of up to $27 million